FiercePharma3d
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.
News Medical7d
VERTEX 80/80v FTIR Spectrometer from Bruker
The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.
BioSpace7d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
AZoM on MSN7d
Bruker Launches the VERTEX NEO Platform
Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...